AngioJet ZelanteDVT thrombectomy catheter receives FDA approval and CE mark

472

The AngioJet Zelante DVT thrombectomy catheter from Boston Scientific has received CE mark and US Food and Drug Administration (FDA) approval for the treatment of deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins.

 

According to Boston Scientific, the ZelanteDVT catheter is the first AngioJet catheter designed specifically to treat DVT. It is designed to offer four times the thrombus removal power of current AngioJet catheters. According to a press release, the ZelanteDVT catheter should be able to efficiently remove large venous clot burdens and facilitate rapid restoration of blood flow, potentially decreasing procedural time, quickly relieving symptoms and reducing late complications.

 

Mitchell Silver, Riverside Hospital in Columbus, Ohio, says, “The unique features of the ZelanteDVT catheter make it well-suited to treat a wide range of thrombotic occlusions thus potentially decreasing bleeding risks and reducing patients’ need for intensive care stays.”